BOLD vs BOLT

Boundless Bio, Inc. vs Bolt Biotherapeutics, Inc. — Valuation Comparison 2026

BOLD

Biotechnology
Boundless Bio, Inc.
Quality
4.0
out of 10
Value Trap
18
SAFE
Price
$1.46
Last close
Models
7/13
Active
VS

BOLT

Biotechnology
Bolt Biotherapeutics, Inc.
Quality
5.9
out of 10
Value Trap
30
LOW
Price
$5.30
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType BOLD Fair ValueBOLD Upside BOLT Fair ValueBOLT Upside
Bayesian DCF Intrinsic $0.76 -48.1% $0.54 -88.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $2.77 +89.6% $17.21 +224.6%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for BOLD vs BOLT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BOLD vs BOLT — Which Stock Is More Undervalued?

BOLT scores higher with a 5.9/10 quality rating vs BOLD's 4.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Boundless Bio, Inc. (BOLD) and Bolt Biotherapeutics, Inc. (BOLT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BOLD currently trades at $1.46 with a QOC of 4.0/10, while BOLT trades at $5.30 with a QOC of 5.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).